As of May 2018, the revised “C” grade recommendation of the USPSTF for PSA screening states, “for men aged between 55–69 years the decision to undergo periodic PSA based screening for prostate cancer should be an individualized one. This evidence concerns the gene KLK3 and prostate carcinoma.